CYTOMEGALOVIRUS (CMV) DNA AMPLIFICATION FROM PLASMA COMPARED WITH CMVPP65 ANTIGEN (PPUL83) DETECTION IN LEUKOCYTES FOR EARLY DIAGNOSIS OF SYMPTOMATIC CMV INFECTION IN KIDNEY-TRANSPLANT PATIENTS
Bz. Wirgart et al., CYTOMEGALOVIRUS (CMV) DNA AMPLIFICATION FROM PLASMA COMPARED WITH CMVPP65 ANTIGEN (PPUL83) DETECTION IN LEUKOCYTES FOR EARLY DIAGNOSIS OF SYMPTOMATIC CMV INFECTION IN KIDNEY-TRANSPLANT PATIENTS, Clinical and diagnostic virology, 7(2), 1996, pp. 99-110
Background: Rapid laboratory methods for the early detection of cytome
galovirus (CMV) are needed for the prevention of CMV disease in transp
lant recipients. These methods should not only be able to detect the v
irus but also be highly predictive for CMV disease. Objective: The cli
nical value of a simple and rapid nested plasma polymerase chain react
ion (PCR) was evaluated by comparing the results with CMV pp65 antigen
detection in leukocytes (CMV antigenemia assay), virus isolation from
leukocytes, CMV IgG and IgM antibody response and clinical data. Stud
y design: A total of 471 EDTA blood samples were collected from 85 kid
ney transplant patients during a 3-4 month period after transplantatio
n. CMV DNA was amplified directly from 10 mu l of plasma while 150 000
separated leukocytes were stained for CMV pp65 antigen by each of two
monoclonal antibodies. A total of one million leukocytes were used fo
r virus isolation. The PCR protocol used in the present study involves
a simple alkaline lysis technique for isolating DNA directly from pla
sma which is easy and rapid to perform. Results: Twenty-eight patients
developed symptomatic CMV infection while asymptomatic infection occu
rred in 29 patients. CMV pp65 antigen detection had a 75% sensitivity
and a 57% positive predictive value for CMV disease development, compa
red with 64% and 79% sensitivity and 49% and 46% positive predictive V
alue for CMV DNA and viremia, respectively. The median time until dete
ction of CMV in patients with symptomatic CMV infection was 26 days af
ter transplantation, compared with 49 days in asymptomatic patients by
any of the methods used. Early appearance (within 8 weeks) of CMV pp6
5 antigen and CMV DNA had high predictive values for symptomatic infec
tion; repeated detection of pp65 antigen and CMV DNA were more common
in symptomatic patients. Conclusions: CMV antigenemia assay and plasma
PCR can be used for pre-symptomatic diagnosis of CMV infection. Virus
isolation and CMV serology in most cases provide a post-symptomatic d
iagnosis. The best marker for monitoring kidney transplant patients mi
ght be the quantitative CMV antigenemia assay. (C) 1996 Elsevier Scien
ce B.V.